Abstract
Osteosarcomas and Ewing’s sarcoma (EWS) are aggressive malignant bone tumors. In both cases, prognostic markers are lacking. Presently, only clinical features are widely accepted as prognostic indicators. In this study we assessed the prognostic value of CCN3 (Nov), a matricellular protein that belong to the CCN family of regulatory proteins, whose members were shown to play crucial roles in bone formation. In osteosarcomas, CCN3 expression levels represent a useful tool to early identification of patients with different prognosis. In both osteosarcomas and Ewing’s sarcomas, the expression of a full length CCN3 protein was associated to a worse prognostic and a higher risk to developing metastasis. In Ewing’s tumors, the expression of a CCN3 protein lacking the internal VWC module was associated with reduced tumorigenic potential and better outcome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bacci G., Forni C., Longhi A., Ferrari S., Donati D., De Paolis M., Barbieri E., Pignotti E., Rosito P., Versari M. (2004). Long-term outcome for patients with non- metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 40: 73–83.
Bacci G., Longhi A., Barbieri E., Ferrari S., Mercuri M., Briccoli A., Versari M., Pignotti E., Picci P. (2005). Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol 27: 517–520.
Barr F.G., Womer R.B. (2007). Molecular diagnosis of Ewing family tumors: too many fusions...? J Mol Diagn 9: 437–440.
Benini S., Perbal B., Zambelli D., Colombo M.P., Manara M.C., Serra M., Parenza M., Martinez V., Picci P., Scotlandi K. (2005). In Ewing’s sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24(27): 4349–4361.
Bernstein M., Kovar H., Paulussen M., Randall R.L., Schuck A., Teot L.A., Juergens H. (2006). Ewing’s sarcoma family of tumors: current management. Oncologist 11: 503–519.
Bleau A.M., Planque N., Perbal B. (2005). CCN proteins and cancer: two to tango. Front Biosci 10: 998–1009. Review.
Bleau A.M., Planque N., Lazar N., Zambelli D., Ori A., Quan T., Fisher G., Scotlandi K., Perbal B. (2007). Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation. J Cell Biochem 101: 1475–1491.
Bork P. (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327, 125–130.
Chevalier G., Yeger H., Martinerie C., Laurent M., Alami J., Schofield P.N., Perbal B. (1998). novH: differential expression in developing kidney and Wilm’s tumors. Am J Pathol 152: 1563–1574.
Chou A.J., Gorlick R. (2006). Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075–1085.
Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., Kovar H., Joubert I., de Jong P., Rouleau G., Aurias A., Thomas G. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162–165.
Enneking W.F., Spanier S.S., Goodman M.A. (1980). Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 62: 1027–1030.
Fukunaga-Kalabis M., Martinez G., Liu Z.J., Kalabis J., Mrass P., Weninger W., Firth S.M., Planque N., Perbal B., Herlyn M. (2006). CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol 175(4): 563–569. Epub 2006 Nov 13.
Grier H.E., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J., Pritchard D.J., Gebhardt M.C., Dickman P.S., Perlman E.J., Meyers P.A., Donaldson S.S., Moore S., Rausen A.R., Vietti T.J., Miser J.S. (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694–701.
Holbourn K.P., Acharya K.R., Perbal B. (2008). The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33: 461–473.
Joliot V., Martinerie C., Dambrine G., Plassiart G., Brisac M., Crochet J., Perbal B. (1992). Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 12: 10–21.
Katsuki Y., Sakamoto K., Minamizato T., Makino H., Umezawa A., Ikeda M.A., Perbal B., Amagasa T., Yamaguchi A., Katsube K. (2008). Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem Biophys Res Commun; 368(3): 808–814. Epub 2008 Feb 12.
Kawaki H., Kubota S., Suzuki A., Lazar N., Yamada T., Matsumura T., Ohgawara T., Maeda T., Perbal B., Lyons K.M., Takigawa M. (2008). Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage. J Bone Miner Res 23(11): 1751–1764.
Kennedy L., Liu S., Shi-Wen X., Chen Y., Eastwood M., Sabetkar M., Carter D.E., Lyons K.M., Black C.M., Abraham D.J., Leask A. (2007). CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res 313: 952–964.
Kubota S., Takigawa M. (2007). Role of CCN2/CTGF/Hcs24 in bone growth. Int Rev Cytol 257: 1–41.
Kyurkchiev S., Yeger H., Bleau A.M., Perbal B. (2004). Potential cellular conformations of the CCN3(NOV) protein. Cell Commun Signal 2(1): 9.
Lazar N., Manara C., Navarro S., Bleau A.M., Llombart-Bosch A., Scotlandi K., Planque N., Perbal B. (2007). Domain-specific CCN3 antibodies as unique tools for structural and functional studies. J Cell Commun Signal 1(2): 91–102.
Leask A., Abraham D.J. (2006). All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803–4810.
Lian J.B., Stein G.S. (2003). Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des 9: 2677–85.
Longhi A., Errani C., De Paolis M., Mercuri M., Bacci G. (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423–36.
Manara M.C., Perbal B., Benini S., Strammiello R., Cerisano V., Perdichizzi S., Serra M., Astolfi A., Bertoni F., Alami J., Yeger H., Picci P., Scotlandi K. (2002). The expression of ccn3 (nov) gene in musculoskeletal tumors. Am J Pathol 160: 849–859.
McCallum L., Price S., Planque N., Perbal B., Pierce A., Whetton A.D., Irvine A.E. (2006). A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108(5): 1716–1723. Epub 2006 May 2.
McCallum L., Lu W., Price S., Lazar N., Perbal B., Irvine A.E. (2009). CCN3: a key growth regulator in chronic myeloid leukaemia. J Cell Commun Signal. 3(2): 115–124.
Minamizato T., Sakamoto K., Liu T., Kokubo H., Katsube K., Perbal B., Nakamura S., Yamaguchi A. (2007). CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem Biophys Res Commun 354: 567–573.
Patanè S., Avnet S., Coltella N., Costa B., Sponza S., Olivero M., Vigna E., Naldini L., Baldini N., Ferracini R., Corso S., Giordano S., Comoglio P.M., Di Renzo M.F. (2006). MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66: 4750–7.
Perbal B., Takigawa M. (2005). The CCN family of proteins: An overview. In: Perbal B., Takigawa M., editors. The CCN proteins: a new family of cell growth and differentiation regulators. Imperial College Press, London, p. 1–18.
Perbal B., Zuntini M., Zambelli D., Serra M., Sciandra M., Cantiani L., Lucarelli E., Picci P., Scotlandi K. (2008). Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res 14: 701–709.
Perbal B. (1999). Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. Mol Pathol 52(2): 84–91.
Perbal B. (2001). NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54(2): 57–79.
Perbal B. (2004). CCN proteins: multifunctional signalling regulators. Lancet 363: 62–64.
Perbal B. (2008). CCN3: Doctor Jekyll and Mister Hyde. J Cell Commun Signal 2(1–2): 3–7.
Perbal B. (2009). Alternative splicing of CCN mRNAs ... it has been upon us. J Cell Commun Signal. 3(2): 151–152.
Perbal B., Noureddine Lazar N., Diana Zambellia D., Jose Antonio Lopez-Guerreroc J.A., Antonio Llombart-Boschd A., Katia Scotlandia K., Piero Piccia P. (2009). Prognostic relevance of ccn3 in Ewing’s sarcoma. Human Pathology (in press, October issue).
Planque N., Perbal B. (2003). A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3: 15.
Planque N., Long Li C., Saule S., Bleau A.M., Perbal B. (2006). Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins. J Cell Biochem 99: 105–116.
Riser B.L., Najmabadi F., Perbal B., Peterson D.R., Rambow J.A., Riser M.L., Sukowski E., Yeger H., Riser S.C. (2009). CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174(5): 1725–1734. Epub 2009.
Subramaniam M.M., Lazar N., Navarro S., Perbal B., Llombart-Bosch A. (2008). Expression of CCN3 protein in human Wilms’ tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies. Virchows Arch 452: 33–39.
Takigawa M., Nishida T., Kubota S. (2005). Roles of CCN2/CTGF in the control of growth and regeneration. In Perbal B., Takigawa M. (eds) The CCN proteins: a new family of cell growth and differentiation regulators. Imperial College Press, London.
Thomas D.M., Johnson S.A., Sims N.A., Trivett M.K., Slavin J.L., Rubin B.P., Waring P., McArthur G.A., Walkley C.R., Holloway A.J., Diyagama D., Grim J.E., Clurman B.E., Bowtell D.D., Lee J.S., Gutierrez G.M., Piscopo D.M., Carty S.A., Hinds P.W. (2004). Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 167: 925–34.
Vallacchi V., Daniotti M., Ratti F., Di Stasi D., Deho P., De Filippo A., Tragni G., Balsari A., Carbone A., Rivoltini L., Parmiani G., Lazar N., Perbal B., Rodolfo M. (2008). CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 68(3): 715–723. Erratum in: Cancer Res. 2008 Mar 15;68(6): 2051.
van Roeyen C.R., Eitner F., Scholl T., Boor P., Kunter U., Planque N., Gröne H.J., Bleau A.M., Perbal B., Ostendorf T., Floege J. (2008). CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73(1): 86–94. Epub 2007 Oct 10.
Yu C., Le A.T., Yeger H., Perbal B., Alman B.A. (2003) NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol 201: 609–615.
Acknowledgements
This work was funded by the “Prothets project contract No. 503036 of the EU” and Italian Association for Cancer Research to K. Scotlandi. BP was supported by the French ministry of Education and Research and was on leave from Université Paris 7. Thanks are due to Annick Perbal for editorial help.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Perbal, B. et al. (2010). Prognostic Relevance of CCN3 in Bone Sarcomas. In: Perbal, A., Takigawa, M., Perbal, B. (eds) CCN Proteins in Health and Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3779-4_17
Download citation
DOI: https://doi.org/10.1007/978-90-481-3779-4_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3778-7
Online ISBN: 978-90-481-3779-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)